Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1)
- Target
- NCR3LG1
- Molecular classification
- B7 family (immunoglobulin superfamily), Immune checkpoint ligand, Ligand
01
Overview
Natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1), commonly called B7-H6, is a member of the B7 family of immune regulatory ligands. It is selectively expressed on the surface of various tumor cells and absent or very low in normal tissues. B7-H6 binds to the activating receptor NKp30 (NCR3) on natural killer (NK) cells, triggering NK cell activation, cytokine production, and direct cytotoxicity. Both membrane-bound and soluble forms of B7-H6 exist: the soluble form can impair NK cell function by masking NKp30 and preventing effective tumor cell killing. High levels of B7-H6 (especially the soluble form) are associated with worse prognosis in several cancers and may contribute to tumor immune evasion. Downregulation or blockade of B7-H6 sensitizes tumor cells to NK-mediated lysis, supporting its consideration as a biomarker, prognostic marker, and emerging immunotherapeutic target in oncology[1][3].
- Other names
- B7-H6B7H6B7 homolog 6Natural cytotoxicity triggering receptor 3 ligand 1DKFZp686O24166NCR3LG1putative Ig-like domain-containing protein DKFZp686O24166/DKFZp686I21167
02
Mechanism of action
Blockade or downregulation of B7-H6 enhances NK cell-mediated cytotoxicity of tumor cells Antibodies blocking the B7-H6/NKp30 interaction restore NK cell function
03
Biological functions
Immune responseRegulation of natural killer (NK) cell activationModulation of NK cell cytotoxicityCytokine production modulation
04
Disease associations
Cancer (including pancreatic cancer, glioma, neuroblastoma, breast cancer, non-small cell lung cancer, hepatocellular carcinoma, gastric carcinoma, ovarian cancer, leukemia, lymphoma)Negative prognostic marker in various cancersTumor immune evasion
05
Safety considerations
Potential for off-tumor effects if B7-H6 is expressed on non-tumor tissuesRisk of excessive immune activation or cytokine release syndrome if NK cell activation is dysregulated
06
Interacting drugs
No approved drugs directly targeting NCR3LG1/B7-H6; therapeutic antibodies and immune modulators in preclinical/clinical research
07
Biomarkers
B7-H6 expression (tissue, soluble in serum) as a prognostic marker for cancer severity and outcome
Beyond the preview
Go deeper on Natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1).